Results 11 to 20 of about 664,100 (294)
Cell Death and Disease, 2023 Bruton’s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops.
Yijing Li +15 more
doaj +1 more source
New England Journal of Medicine, 1977 TWO decades have passed since Denis Burkitt, a British surgeon working in Uganda, originally described the tumor that now bears his name.1 The discovery that this tumor has distinctive clinical and...
openaire +7 more sources
Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?
Hemato, 2022 Multiple myeloma (MM) is the second deadliest hematological cancer. Despite the enormous innovation on MM treatment in the last decades, still 48% of patients die within 5 years after diagnosis. MM diagnosis and therapeutic strategy mainly rely on direct
Emilie Arnault Carneiro +3 more
doaj +1 more source
Cancer Cell, 2002 363 Epidemiology Lymphomas comprise the fifth most common cancer type in the United States, with approximately 55,000 cases of nonHodgkin’s lymphoma (NHL) and 7,400 cases of Hodgkin’s lymphoma (HL) each year. An unexplained finding is the 80% rise in NHL between 1973 and 1997 (http://www.seer.cancer.gov).
Louis M. Staudt, Wyndham H. Wilson
openaire +3 more sources
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
Journal of Hematology & Oncology, 2018 Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable.
Swathi Balaji +5 more
doaj +1 more source
Haematologica, 2020 The impact of pre-treatment maximum standardized uptake value (SUVmax) on the outcome of follicular lymphoma (FL) following specific frontline regimens has not been explored.
Paolo Strati +15 more
doaj +1 more source
Case Reports in Hematology, 2012 Primary non-Hodgkins lymphoma of the uterine cervix is a very rare diagnosis. A 54-year-old woman presented with a 3-month history of postmenopausal bleeding per vaginum. On examination, a friable, fungating lesion was seen on the cervix. Histology revealed a CD 20 positive high-grade non-Hodgkin’s diffuse large B cell lymphoma from cervical biopsies ...
David James Camilleri +4 more
openaire +3 more sources
Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia
FEBS Letters, EarlyView.This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley +1 more source
Cancer MedicineBackground Lymphoma is the most common secondary cause of hemophagocytic lymphohistiocytosis (HLH) in adults. Lymphoma‐associated HLH (LA‐HLH) in the elderly population is not rare, however, little has been reported regarding clinicopathological ...
Yi Miao +30 more
doaj +1 more source
FEBS Letters, EarlyView.In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley +1 more source